Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An announcement from Day One Biopharmaceuticals ( (DAWN) ) is now available.
Samuel Blackman, co-founder of Day One Biopharmaceuticals, plans to retire as Head of Research & Development by the end of 2024, transitioning to a strategic advisor role. His departure marks a significant leadership change as the company searches for his successor, acknowledging his pivotal contributions since its inception.
See more insights into DAWN stock on TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
